SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|
| ELDEPRYL 5MG TABS | 5 mg | Tablet · Oral use | 100 Tablet Container | SAR 202.90 | NCE · Prescription | ORION PHARMA | Withdrawn by MAH · Not Marketed |
US FDA United States — FDA approvals (Drugs@FDA)
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|
| SELEGILINE | 02230641 | 5 MG | TABLET · ORAL | AA PHARMA INC |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|
| US NADAC | EMSAM 12 MG/24 HOURS PATCH | $75.39812 | per EA | 23 Sep 2026 |
| US NADAC | EMSAM 6 MG/24 HOURS PATCH | $74.99706 | per EA | 23 Sep 2026 |
| US NADAC | EMSAM 9 MG/24 HOURS PATCH | $75.17807 | per EA | 23 Sep 2026 |
| US NADAC | SELEGILINE HCL 5 MG CAPSULE | $0.75631 | per EA | 23 Sep 2026 |
| US NADAC | SELEGILINE HCL 5 MG TABLET | $0.76567 | per EA | 23 Sep 2026 |
| NHS Drug Tariff | Selegiline 10mg tablets | £32.23 | 100 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Selegiline 5mg tablets | £16.52 | 100 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Safety signals and safety-related labeling changes
- US FDA 16 Jun 2021 ZELAPAR — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 14 Jul 2017 EMSAM — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide
All safety entries for selegiline →
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.